Alto Neuroscience, Inc. (NYSE:ANRO) Given Average Recommendation of "Moderate Buy" by Analysts

Key Points

• Analysts give Alto Neuroscience an average recommendation of “Moderate Buy” from 8 analysts (6 buys, 1 hold, 1 sell) with an average 1‑year price target of $35.14.
• Shares opened at $24.42, trade in a 12‑month range of $2.12–$28.44 and have a market cap of $780M and a negative PE (−11.20); the company reported Q1 EPS of ($0.45) versus estimates of ($0.56), while analysts forecast a full‑year EPS of −2.48.
• Alto is a clinical‑stage biotech that uses an integrated digital neuroscience platform (EEG, cognitive assessments and machine learning) to predict individual treatment responses and advance precision medicine for neuropsychiatric disorders.

Shares of Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) have earned an average recommendation of "Moderate Buy" from the eight analysts that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $35.1429.

A number of research firms recently issued reports on ANRO. Wall Street Zen cut shares of Alto Neuroscience from a "hold" rating to a "sell" rating in a research report on Saturday, March 21st. JonesTrading cut their target price on shares of Alto Neuroscience from $49.00 to $44.00 and set a "buy" rating on the stock in a research report on Thursday, April 2nd. BTIG Research boosted their target price on shares of Alto Neuroscience from $27.00 to $28.00 and gave the stock a "buy" rating in a research note on Tuesday, February 17th. HC Wainwright reiterated a "buy" rating and set a $50.00 price target on shares of Alto Neuroscience in a report on Thursday, April 2nd. Finally, Chardan Capital reiterated a "buy" rating and issued a $30.00 price target on shares of Alto Neuroscience in a research note on Wednesday.

Alto Neuroscience Stock Performance

Alto Neuroscience stock opened at $24.42 on Friday. Alto Neuroscience has a 12-month low of $2.12 and a 12-month high of $28.44. The company has a quick ratio of 15.69, a current ratio of 15.69 and a debt-to-equity ratio of 0.12. The business's 50-day moving average price is $21.91 and its two-hundred day moving average price is $16.93. The stock has a market cap of $780.06 million, a PE ratio of -11.20 and a beta of 2.01.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last posted its earnings results on Monday, March 16th. The company reported ($0.45) EPS for the quarter, topping analysts' consensus estimates of ($0.56) by $0.11. As a group, analysts expect that Alto Neuroscience will post -2.48 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Alto Neuroscience

Several large investors have recently bought and sold shares of the company. Vanguard Personalized Indexing Management LLC increased its stake in shares of Alto Neuroscience by 13.7% in the third quarter. Vanguard Personalized Indexing Management LLC now owns 17,045 shares of the company's stock valued at $69,000 after buying an additional 2,055 shares during the period. Peapod Lane Capital LLC boosted its position in Alto Neuroscience by 1.1% during the 3rd quarter. Peapod Lane Capital LLC now owns 281,963 shares of the company's stock worth $1,136,000 after buying an additional 3,106 shares during the period. Torren Management LLC acquired a new stake in Alto Neuroscience during the 4th quarter worth approximately $62,000. XTX Topco Ltd grew its holdings in Alto Neuroscience by 32.2% during the 4th quarter. XTX Topco Ltd now owns 20,824 shares of the company's stock worth $371,000 after acquiring an additional 5,078 shares during the last quarter. Finally, Citizens Financial Group Inc. RI grew its holdings in Alto Neuroscience by 19.0% during the 3rd quarter. Citizens Financial Group Inc. RI now owns 40,000 shares of the company's stock worth $161,000 after acquiring an additional 6,394 shares during the last quarter.

Alto Neuroscience Company Profile

Alto Neuroscience NYSE: ANRO is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto's proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.